Consensus Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
26.55 ^USD	+1.45%		+2.19%	-15.79%

Mar. 27	Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing	MT
Mar. 21	Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Arcturus Therapeutics Holdings Inc.

Price target over the last 5 years

History of analyst recommendation changes

7f76a1d2b42b41f6539d90c331537d0b.n-9tsTxKkzaVfif72-gXc0cecaAuwFpcCi7wMfLfNzk.8J85hlV8oUzbLXWSsaJVNhJ8M5d8pTsSaX-vCZSHWGnQnxfEZAL0XKY9Ew~e42975f4f3243de955b93718e014945a

Analyst Recommendations on Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	Mar. 21	MT
Canaccord Genuity Adjusts Arcturus Therapeutics Holdings' PT to $87 From $81, Maintains Buy Rating	Mar. 11	MT
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $58 From $45, Maintains Overweight Rating	Mar. 08	MT
Citigroup Raises Price Target on Arcturus Therapeutics to $48 From $40, Maintains Buy Rating	Feb. 08	MT
Canaccord Genuity Initiates Arcturus Therapeutics With Buy Rating, $81 Price Target	Dec. 13	MT
William Blair Initiates Arcturus Therapeutics Holdings at Outperform Rating	23-07-24	MT
HC Wainwright Upgrades Arcturus Therapeutics Holdings to Buy From Neutral, Price Target at $51	23-05-11	MT
Goldman Sachs Adjusts Price Target on Arcturus Therapeutics Holdings to $14 From $8, Maintains Sell Rating	22-11-10	MT
Baird Downgrades Arcturus Therapeutics Holdings to Underperform From Neutral, Price Target is $18	22-11-10	MT
Barclays Upgrades Arcturus Therapeutics Holdings to Equalweight From Underweight, Adjusts Price Target to $25 From $16	22-11-02	MT
Arcturus Therapeutics Shares Rise 31% After Vaccine Collaboration	22-11-02	DJ
Cantor Fitzgerald Raises Price Target on Arcturus Therapeutics Holdings to $44 From $39, Keeps Overweight Rating	22-11-02	MT
US Futures Nudge Higher Ahead of Federal Reserve Board Meeting; Fourth Straight Rate Hike Expected	22-11-02	MT
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $98 From $105, Reiterates Overweight Rating	22-08-10	MT
Barclays Trims Price Target on Arcturus Therapeutics Holdings to $16 From $17, Reiterates Underweight Rating	22-08-10	MT
Raymond James Downgrades Arcturus Therapeutics Holdings to Underperform From Market Perform	22-08-10	MT
Cantor Fitzgerald Assumes Arcturus Therapeutics Holdings at Overweight, Sets $39 Price Target	22-07-19	MT
Goldman Sachs Adjusts Arcturus Therapeutics Holdings' Price Target to $8 from $14, Keeps Sell Rating	22-05-24	MT
Baird Upgrades Arcturus Therapeutics Holdings to Neutral From Underperform, Cuts Price Target to $18 From $21	22-05-11	MT
Barclays Adjusts Arcturus Therapeutics Holdings' Price Target to $17 from $21, Keeps Underweight Rating	22-05-10	MT
HC Wainwright Lowers Arcturus Therapeutics Holdings Price Target to $19 From $25, Neutral Rating Kept	22-05-10	MT
Citigroup Downgrades Arcturus Therapeutics Holdings to Neutral From Buy; Price Target is $29	22-04-21	MT
Wells Fargo Adjusts Arcturus Therapeutics Holdings' Price Target to $105 from $107, Keeps Overweight Rating	22-03-25	MT
Citigroup Adjusts Price Target on Arcturus Therapeutics Holdings to $86 From $114, Maintains Buy Rating	22-03-15	MT
Barclays Adjusts Price Target on Arcturus Therapeutics Holdings to $21 From $31, Reiterates Underweight Rating	22-03-01	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.17 USD

Average target price

67.89 USD

Spread / Average Target

+159.41%

High Price Target

140 USD

Spread / Highest target

+434.96%

Low Price Target

18 USD

Spread / Lowest Target

-31.22%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Arcturus Therapeutics Holdings Inc.

Canaccord Genuity
Wells Fargo Securities
Citigroup
William Blair & Co.
HC Wainwright
Baird
Goldman Sachs
Cantor Fitzgerald
Barclays
Raymond James
Chardan
B. Riley

Ratings for Arcturus Therapeutics Holdings Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar